Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 6 June 2017, 19:39 HKT/SGT
Share:
Shandong Luoxin Pharmaceutical's H Shares Trading is Suspended from 6 June 2017 until its Delisting on 16 June 2017
- The Liquidity of the H Shares May be Severely Reduced after Delisting on 16 June 2017
- The Latest Time and Date for the Offer Remaining Open for Acceptance is 4:00 p.m. on 26 June 2017

HONG KONG, June 6, 2017 - (ACN Newswire) - Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. ("Shandong Luoxin Pharmaceutical" or the "Company") (stock code: 8058) has announced that the trading in its H Shares has been suspended from today and will remain suspended until the withdrawal of listing of the H Shares from the Stock Exchange from 9:00 a.m. on 16 June 2017.

Giant Star Global (HK) Limited and Ally Bridge Flagship LX (HK) Limited, being the Joint Offerors, have no rights under the laws of the PRC and the articles of association of the Company to compulsorily acquire the H Shares that are not tendered for acceptance pursuant to the Offer. Accordingly, the H Shareholders are reminded that if they do not accept the Offer and the Offer subsequently becomes unconditional in all respects, and the H Shares are delisted from the Stock Exchange, this will result in the H Shareholders holding securities that are not listed on the Stock Exchange and the liquidity of the H Shares may be severely reduced.

Unless the Offer is extended, the latest time and date for acceptance of the Offer will be 4:00 p.m. on 26 June 2017 ("Closing Date") and the latest date for posting of remittances for the amounts due under the Offer in respect of valid acceptances received at or before the latest time for acceptances of the Offer on the Closing Date will be 5 July 2017.



June 6, 2017 19:39 HKT/SGT
Topic: Press release summary
Sectors: Daily Finance, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO(R) (fosnetupitant/ palonosetron) in the United States  
Apr 20, 2018 22:10 HKT/SGT
Nexusguard, NG Crossing join forces to protect MENA enterprises from DDoS attacks  
Apr 20, 2018 21:00 HKT/SGT
Hong Kong Houseware Fair and Home Textiles Fair Open with 2,600+ Exhibitors  
Apr 20, 2018 20:00 HKT/SGT
Eisai to Present Latest Data on Perampanel and Rufinamide at Annual American Academy of Neurology Meeting  
Apr 20, 2018 17:50 HKT/SGT
New FM framework provides best practice on more strategic decision making for facility managers globally  
Apr 20, 2018 17:30 HKT/SGT
Mitsubishi Heavy Industries-Haier (Qingdao) Air-Conditioners Co., Ltd., Joint Venture with Haier  
Apr 20, 2018 17:29 HKT/SGT
DOCOMO Applauds xRAN Forum's Open Fronthaul Specification  
Apr 20, 2018 17:09 HKT/SGT
Fujitsu Upgrades RIKEN's AI Research Computer "RAIDEN;" Reaches Top Tier of Processing Performance in Japan  
Apr 20, 2018 15:41 HKT/SGT
Trillium Appoints Global Director of Engineering  
Apr 20, 2018 14:00 HKT/SGT
Lubrizol Presents Estane(R) TPU and Other Innovations for Consumer, Industrial, Footwear and Electronics Applications at Chinaplas 2018  
Apr 20, 2018 12:10 HKT/SGT
More Press release >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: